scholarly article | Q13442814 |
P356 | DOI | 10.1038/AJG.2011.387 |
P8608 | Fatcat ID | release_cyhdpuczlrg2zn677k643zhdpi |
P698 | PubMed publication ID | 22334249 |
P2093 | author name string | Cheol-In Kang | |
Kyu Taek Lee | |||
Jong Kyun Lee | |||
Kwang Hyuck Lee | |||
Young Kyung Sung | |||
P2860 | cites work | Emergency surgery for severe acute cholangitis. The high-risk patients | Q24540384 |
Acute cholangitis. Multivariate analysis of risk factors | Q24550551 | ||
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America | Q28268745 | ||
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary | Q33540823 | ||
Acute (ascending) cholangitis. | Q34033188 | ||
Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome | Q34106854 | ||
Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome | Q34351978 | ||
The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida | Q34666332 | ||
Intra-abdominal Sepsis in Elderly Persons | Q34681098 | ||
Acute biliary septic shock | Q36712023 | ||
Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines | Q36718098 | ||
Clinical significance of extended-spectrum beta-lactamases. | Q37291354 | ||
Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. | Q37361423 | ||
Antibiotics in the treatment of biliary infection | Q40184576 | ||
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America | Q41445493 | ||
Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae | Q42167308 | ||
Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance | Q43065214 | ||
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). | Q44007271 | ||
Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes | Q44436393 | ||
Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome | Q45097000 | ||
Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome | Q46173410 | ||
Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. | Q46257399 | ||
Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization | Q49046570 | ||
Septicemia from biliary tract infection | Q50159216 | ||
Epidemiology and prognostic determinants of patients with bacteremic cholecystitis or cholangitis. | Q50162196 | ||
Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. | Q51051228 | ||
Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. | Q54381514 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | clinical epidemiology | Q5834738 |
P304 | page(s) | 473-483 | |
P577 | publication date | 2012-02-14 | |
P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
P1476 | title | The clinical epidemiology and outcomes of bacteremic biliary tract infections caused by antimicrobial-resistant pathogens | |
P478 | volume | 107 |
Q33851181 | A Patient Presenting with Cholangitis due to Stenotrophomonas Maltophilia and Pseudomonas Aeruginosa Successfully Treated with Intrabiliary Colistine |
Q26782881 | Acute Bacterial Cholangitis |
Q39723374 | Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis |
Q55362422 | Anaerobic coverage as definitive therapy does not affect clinical outcomes in community-onset bacteremic biliary tract infection without anaerobic bacteremia. |
Q37192102 | Antimicrobial resistance in Asia: current epidemiology and clinical implications |
Q33735481 | Appendectomy as a Risk Factor for Bacteremic Biliary Tract Infection Caused by Antibiotic-Resistant Pathogens |
Q26780350 | Calculated Antibiosis of Acute Cholangitis and Cholecystitis |
Q93048752 | Clinical epidemiology and outcomes of biliary tract infections caused by Klebsiella pneumoniae |
Q43719510 | Clinical impact of inappropriate initial antimicrobial therapy on outcome in bacteremic biliary tract infections |
Q37607641 | Determination of antibiotic consumption index for animal originated foods produced in animal husbandry in Iran, 2010 |
Q57106909 | Etiologies, risk factors, and outcomes of bacterial cholangitis after living donor liver transplantation |
Q90086575 | Guidelines for Antibiotic Prescription in Intensive Care Unit |
Q89681409 | Impact of the Sensitivity to Empiric Antibiotics on Clinical Outcomes after Biliary Drainage for Acute Cholangitis |
Q92668877 | Pathophysiologic Characterization of a Novel Rabbit Model of Biliary Tract Infection-Derived Sepsis |
Q92735381 | Shortening antibiotic duration in the treatment of acute cholangitis: rationale and study protocol for an open-label randomized controlled trial |
Q42277917 | TG13 antimicrobial therapy for acute cholangitis and cholecystitis |
Q46770277 | Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. |
Q38735828 | Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis |